Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Xbrane Biopharma AB

Market Cap 22Cr 2.34Cr 2.03Cr 1.87Cr 1.75Cr 3.27Cr 223.4Cr 3.33Cr 8.6Cr 108.05Cr 8.8Cr 8.61Cr 375.47Cr P/E ratio 2026 *
-
P/E ratio 2027 * -
Enterprise value 22Cr 2.34Cr 2.03Cr 1.87Cr 1.75Cr 3.27Cr 223.4Cr 3.33Cr 8.6Cr 108.05Cr 8.8Cr 8.61Cr 375.47Cr EV / Sales 2026 *
1.19x
EV / Sales 2027 * 1.01x
Free-Float
58.96%
Yield 2026 *
-
Yield 2027 * -
1 day+4.37%
1 week+7.72%
Current month+2.87%
1 month+11.98%
3 months+82.23%
6 months+7.72%
Current year+5.39%
1 week 10.25
Extreme 10.25
11.5
1 month 8.94
Extreme 8.94
11.8
Current year 5.42
Extreme 5.421
13.8
1 year 5.42
Extreme 5.421
38.1
3 years 5.42
Extreme 5.421
11,137.5
5 years 5.42
Extreme 5.421
22,550
10 years 5.42
Extreme 5.421
22,550
Manager TitleAgeSince
Chief Executive Officer 46 01/01/2015
Director of Finance/CFO - 09/01/2025
Chief Tech/Sci/R&D Officer 44 09/10/2017
Director TitleAgeSince
Director/Board Member 55 01/01/2020
Director/Board Member 62 16/05/2019
Director/Board Member 63 05/05/2022
Date Insider Type Main position Quantity % Market Cap.
27/24/27Buy

Director

22,500 0.0015%
26/24/26Free

Director

1,25,000 0.0082%
18/24/18Buy

Director

26,087 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
+4.37%+7.72%-63.06%-99.89% 2.25Cr
+1.23%-0.22%-13.62%-11.99% 4.3TCr
+0.71%-1.16%+268.53%+485.55% 3.16TCr
+1.39%+3.11%+20.82%-9.85% 3.07TCr
-0.97%-2.37%+1.66%+24.13% 3.01TCr
+6.65%-5.00%+11.42%+15.34% 2.25TCr
+0.15%+5.93%+11.00%+8.63% 1.32TCr
+1.94%+4.76%+56.47%+124.57% 1.31TCr
+3.61%-1.56% - - 1.28TCr
+1.41%+2.21%+102.88%+83.47% 1.22TCr
Average +2.05%-0.50%+44.01%+68.88% 2.09TCr
Weighted average by Cap. +1.58%-1.36%+55.88%+93.42%

Financials

2026 *2027 *
Net sales 19Cr 1.96Cr 1.7Cr 1.56Cr 1.46Cr 2.74Cr 186.98Cr 2.79Cr 7.19Cr 90Cr 7.36Cr 7.2Cr 314.26Cr 22Cr 2.32Cr 2.01Cr 1.85Cr 1.74Cr 3.24Cr 221.48Cr 3.3Cr 8.52Cr 107.12Cr 8.72Cr 8.53Cr 372.23Cr
Net income - -
Net Debt - -
Logo Xbrane Biopharma AB
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Employees
28
Date Price Change Volume
09/26/09 10.75 kr +4.37% 67,343
08/26/08 10.30 kr -3.74% 17,351
05/26/05 10.70 kr +0.94% 81,017
04/26/04 10.60 kr +7.07% 98,504
03/26/03 9.900 kr -0.80% 13,175

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XBRANE Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW